Immune checkpoint inhibitor–associated myocarditis: Case reports and a review of the literature

Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum...

Descripción completa

Detalles Bibliográficos
Autores principales: Osinga, T. E., Oosting, S. F., van der Meer, P., de Boer, R. A., Kuenen, B. C., Rutgers, A., Bergmann, L., Oude Munnink, T. H., Jalving, M., van Kruchten, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123105/
https://www.ncbi.nlm.nih.gov/pubmed/35061242
http://dx.doi.org/10.1007/s12471-021-01655-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123105/
https://www.ncbi.nlm.nih.gov/pubmed/35061242
http://dx.doi.org/10.1007/s12471-021-01655-7

Ejemplares similares